BTCC
/
BTCC Square
/
Global Cryptocurrency
/
AbbVie Secures Legal Victory, Delaying Generic Competition for Rinvoq Until 2037
AbbVie Secures Legal Victory, Delaying Generic Competition for Rinvoq Until 2037
20
2
BTCCSquare news:
AbbVie shares surged 4.2% after settling litigation with generic drugmakers, effectively blocking competition for its autoimmune drug Rinvoq until at least April 2037. The resolution removes a key overhang on one of AbbVie's fastest-growing assets, which generated $3.75 billion in the first half of 2025.
Rinvoq's strong performance in treating ulcerative colitis and Crohn's disease positions it as a cornerstone of AbbVie's post-Humira growth strategy. While playing second fiddle to Skyrizi in the autoimmune portfolio, the extended market exclusivity provides clear visibility for revenue streams through the next decade.
By:
